RESUMEN
Genomic and trascriptomic profiling has recently contributed details to the characterization of luminal B breast cancer. We explored the contribution of anthropometric, metabolic, and molecular determinants to the multifaceted heterogeneity of this breast cancer subtype, with a specific focus on the association between body mass index (BMI), pre-treatment fasting glucose, hormone receptors, and expression of human epidermal growth factor receptor 2 (HER2). Extensively annotated specimens were obtained from 154 women with luminal B breast cancer diagnosed at two Italian comprehensive cancer centres. Participants' characteristics were descriptively analyzed overall and by HER2 status (positive vs. negative). BMI (<25 vs ≥25), pre-treatment fasting glucose (Asunto(s)
Neoplasias de la Mama/genética
, Neoplasias de la Mama/metabolismo
, Receptor ErbB-2/biosíntesis
, Adulto
, Anciano
, Antropometría
, Glucemia/análisis
, Índice de Masa Corporal
, Femenino
, Humanos
, Inmunohistoquímica
, Persona de Mediana Edad
, Receptores de Estrógenos/biosíntesis